Cynosure (Nasdaq: CYNO ) is expected to report Q4 earnings on Feb. 12. Here's what Wall Street wants to see:
The 10-second takeaway
Comparing the upcoming quarter to the prior-year quarter, average analyst estimates predict Cynosure's revenues will increase 20.1% and EPS will expand 187.5%.
The average estimate for revenue is $41.0 million. On the bottom line, the average EPS estimate is $0.23.
Last quarter, Cynosure logged revenue of $37.1 million. GAAP reported sales were 31% higher than the prior-year quarter's $28.3 million.
Source: S&P Capital IQ. Quarterly periods. Dollar amounts in millions. Non-GAAP figures may vary to maintain comparability with estimates.
Last quarter, EPS came in at $0.25. GAAP EPS were $0.25 for Q3 against -$0.06 per share for the prior-year quarter.
Source: S&P Capital IQ. Quarterly periods. Non-GAAP figures may vary to maintain comparability with estimates.
For the preceding quarter, gross margin was 58.2%, 170 basis points better than the prior-year quarter. Operating margin was 9.0%, 1,040 basis points better than the prior-year quarter. Net margin was 9.2%, 1,200 basis points better than the prior-year quarter.
The full year's average estimate for revenue is $151.8 million. The average EPS estimate is $0.75.
The stock has a two-star rating (out of five) at Motley Fool CAPS, with 367 members out of 382 rating the stock outperform, and 15 members rating it underperform. Among 92 CAPS All-Star picks (recommendations by the highest-ranked CAPS members), 85 give Cynosure a green thumbs-up, and seven give it a red thumbs-down.
Of Wall Street recommendations tracked by S&P Capital IQ, the average opinion on Cynosure is buy, with an average price target of $32.00.
Is Cynosure the best health care stock for you? Learn how to maximize your investment income and "Secure Your Future With 9 Rock-Solid Dividend Stocks," including one above-average health care logistics company. Click here for instant access to this free report.
- Add Cynosure to My Watchlist.